Ticker

EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 27.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 109,749 shares of the medical research company's stock after buying an additional

Birch Hill Investment Advisors LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE: EW) by 1.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 743,680 shares of the medical research company's stock after selling 13,385

We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's…

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor…